Results 81 to 90 of about 1,266 (177)

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD

, 2020
The 3-min constant speed shuttle test (CSST) was used to examine the effect of tiotropium/olodaterol compared with tiotropium at reducing activity-related breathlessness in patients with chronic obstructive pulmonary disease (COPD). This was a randomised,
Macesic, Hemani, AUMANN, Joseph, Hamilton, Alan, Maltais, Francois, Jin, Xidong, Nadreau, Eric, O'Donnell, Denis E., Kirsten, Anne-Marie   +7 more
core   +1 more source

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Disease. [PDF]

, 2015
Combining long-acting muscarinic antagonists (LAMAs) and long-acting β2-agonists (LABAs) is beneficial in chronic obstructive pulmonary disease (COPD), as the two classes of bronchodilator have complementary modes of action.
Alan Hamilton, Valeria C. Amatto, Zhao, Yihua, René Aalbers, M. Reza Maleki-Yazdi, Waitere-Wijker, Stella, Schmidt, Olaf, Olaf Schmidt, Aalbers, René, Stella Waitere-Wijker, Bjermer, Leif, Bjermer, Leif,, Maleki-Yazdi, M Reza, Hamilton, Alan, Amatto, Valeria C, Yihua Zhao, Leif Bjermer, Lund University.   +17 more
core   +1 more source

Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi

, 2017
Equine airways represent a suitable ex vivo model to study the functional impact of pharmacological treatments on human chronic obstructive pulmonary disorders, such as asthma and chronic obstructive pulmonary disease (COPD). We aimed to characterize the
Calzetta, L, Calzetta L, Cazzola, M, Cito G., Alfonsi P., Rogliani, Paola, Luigino Calzetta, Cazzola M., Pietro Alfonsi, Paola Rogliani, Maurizio Mattei, Giuseppe Cito, Mario Cazzola, Matera, Mg, Cito, Giuseppe, Rogliani P., Maria Gabriella Matera, Matera MG, Mattei M., Cazzola M, Calzetta, Luigino, Alfonsi, Pietro, Alfonsi, P, Rogliani P, Alfonsi P, Calzetta L., Pistocchini E., Mattei, M, Elena Pistocchini, Pistocchini, E, Cazzola, Mario, Rogliani, P, Cito, G, Matera M. G., Pistocchini, Elena, Pistocchini E, Cito G, Mattei, Maurizio, Mattei M, Matera, Maria Gabriella   +39 more
core   +1 more source

Combined bronchodilators (tiotropium plus olodaterol) for patients with chronic obstructive pulmonary disease [PDF]

, 2016
Chronic obstructive pulmonary disease (COPD), a respiratory disease characterized by a progressive decline in lung function, is considered to be a leading cause of morbidity and mortality.
El Khoury, Ghada, Kabbara, Wissam K., Al Assir, Sarah A., Ramadan, Wijdan H.   +3 more
core   +1 more source

Factors Associated with Reduction of Sedentary Time Following Tiotropium/Olodaterol Therapy in Treatment-Naïve Chronic Obstructive Pulmonary Disease

International Journal of COPD, 2021
Koichiro Takahashi,1 Hiroki Tashiro,1 Ryo Tajiri,2 Ayako Takamori,2 Masaru Uchida,3 Go Kato,4 Yuki Kurihara,1 Hironori Sadamatsu,1 Takashi Kinoshita,5 Makoto Yoshida,6 Atsushi Kawaguchi,2,7 Shinya Kimura,1 Naoko Sueoka-Aragane,1 Tomotaka Kawayama5 On ...
Takahashi K, Tashiro H, Tajiri R, Takamori A, Uchida M, Kato G, Kurihara Y, Sadamatsu H, Kinoshita T, Yoshida M, Kawaguchi A, Kimura S, Sueoka-Aragane N, Kawayama T   +13 more
doaj  

Clinical and economic evaluation of using fixed dose dual bronchodilator combination tiotropiumolodaterol in patients with chronic obstructive pulmonary disease

Медицинский совет, 2018
The paper is devoted to the problem of clinical efficacy and pharmacoeconomic evaluation of Spiolto Respimat. The results of clinical trials prove that Spiolto Respimat in patients with COPD improves spirometric values, symptoms of dyspnea and health ...
S. K. Zyryanov, Y. A. Galatonova
doaj   +1 more source

Comprehensive assessment of the safety of olodaterol 5 mu g in the Respimat (R) device for maintenance treatment of COPD: comparison with the long-acting beta(2)-agonist formoterol [PDF]

, 2017
This analysis provides a comprehensive clinical assessment of the long-term safety of the licensed dose of olodaterol (5 mu g once daily [QD] via Respimat (R) inhaler) in patients with chronic obstructive pulmonary disease by exploring the occurrence of ...
Watz, Henrik, Kay Tetzlaff, Henrik Watz, Maleki-Yazdi, M. Reza, Tetzlaff, Kay, M. Reza Maleki-Yazdi, Ulrich Bothner, McGarvey, Lorcan, Bothner, Ulrich, Andrea Koch, Lorcan McGarvey, Koch, Andrea, Florian Voß, Voss, Florian   +13 more
core   +1 more source

A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD

International Journal of COPD, 2020
Stefan Andreas,1,2 Ulrich Bothner,3 Alberto de la Hoz,3 Isabel Kloer,3 Matthias Trampisch,3 Peter Alter4 1Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; 2LungClinic Immenhausen, Immenhausen ...
Andreas S, Bothner U, de la Hoz A, Kloer I, Trampisch M, Alter P   +5 more
doaj  

Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials

, 2018
Background: An extensive clinical trial program supports the efficacy and safety of tiotropium/olodaterol in chronic obstructive pulmonary disease (COPD).
Anzueto, A, Hoz, ADL, Bothner, U, Buhl, R, Voß, F, Ferguson, GT, Calverley, PMA   +6 more
core   +1 more source

Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium–olodaterol for patients with COPD in the Netherlands

International Journal of COPD, 2016
Job FM van Boven,1,2 Janwillem WH Kocks,2 Maarten J Postma1,3,4 1Department of Pharmacy, Unit of PharmacoEpidemiology & PharmacoEconomics, 2Department of General Practice, Groningen Research Institute for Asthma and COPD (GRIAC), 3Institute of ...
van Boven JF, Kocks JWH, Postma MJ
doaj